Trends News Trends In Small Cell Lung Cancer Incidence And Survival

Imdelltra Improves Survival For Some With Small Cell Lung Cancer

Among patients with small cell lung cancer (SCLC), treatment with Imdelltra (tarlatamab-dlle) was found to improve overall survival (OS) when compared with chemotherapy, regardless of ... Read More

Imdelltra Shows Survival Benefit in Small Cell Lung Cancer

Imdelltra significantly improved progression-free and overall survival compared to chemotherapy in small cell lung cancer patients, with a median overall survival of 13.6 months versus 8.3 months. The ... Read More

Analysis of NRG trial in limited-stage small cell lung cancer suggests QOL benefit with twice- vs. once-daily radiation

Previously, the primary endpoint results of the NRG-LU005 study assessing the addition of the immunotherapy drug atezolizumab to standard of care concurrent chemoradiation for limited-state small cell ... Read More

Immunotherapy plus chemotherapy before lung cancer surgery significantly improves long-term survival, analysis finds

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ... Read More

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer. Whether ... Read More

Survival benefit of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung diseases: a nationwide population-based study

Background Compared with cytotoxic chemotherapy, the efficacy and safety of immune checkpoint inhibitors (ICIs) for patients with interstitial lung disease and non-small cell lung cancer (ILD-NSCLC) ... Read More

Nivolumab Plus Chemotherapy Before Surgery Improves Survival in Lung Cancer

Adding nivolumab to neoadjuvant chemotherapy significantly improved 5-year overall survival among patients with resectable non-small cell lung cancer (NSCLC), according to findings from a phase 3 ... Read More

ASTRO: SABR Offers Long-Term Benefits Comparable to Surgery for Non-Small Cell Lung Cancer

For patients with non-small cell lung cancer, stereotactic ablative radiotherapy offers long-term survival outcomes comparable to surgery. Read More

KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ... Read More

Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer

Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to ... Read More